Fortress Biotech Inc Stock Price, News & Analysis

Journey Medical (NASDAQ: DERM) has announced the launch and first prescriptions of Emrosi™, a 40 mg Minocycline Hydrochloride Modified-Release Capsule treatment for inflammatory lesions of rosacea in adults. The medication, which received FDA approval in November 2024, is now available through specialty pharmacy chains.

Emrosi is the lowest-dose oral minocycline available, featuring a unique 10 mg immediate release and 30 mg extended release formulation. Clinical trials demonstrated superior efficacy compared to Oracea® and placebo while maintaining a comparable safety profile. The most common adverse reaction reported was dyspepsia, occurring in ≥1% of subjects.

Journey Medical (Nasdaq: DERM) has scheduled the release of its year end 2024 financial results on Wednesday, March 26, 2025, after U.S. financial markets close. The commercial-stage pharmaceutical company, which specializes in marketing FDA-approved prescription pharmaceutical products for dermatological conditions, will host a conference call and audio webcast at 4:30 p.m. ET on the same day.

Interested U.S. participants can dial 1-866-777-2509 (domestic) or 1-412-317-5413 (international) to join the conference call. Registration is available at https://dpregister.com/sreg/10197674/feaf5b7354. A live audio webcast will be accessible on the company's website and remain available for approximately 30 days after the call.

Fortress Biotech (FBIO) and Partex NV have announced a strategic collaboration to leverage artificial intelligence for biopharmaceutical asset identification and evaluation. The partnership combines Fortress' expertise in identifying and developing promising assets with Partex's proprietary AI-based drug discovery platform.

Partex's technology will provide comprehensive analyses including target identification, indication expansion, and molecular profiling to accelerate bringing therapeutics to market. The collaboration aims to support Fortress' business model of acquiring and advancing assets to enhance shareholder value through product revenue, equity holdings, and dividend and royalty revenue.

Fortress currently has a late-stage pipeline, two recently approved medicines, and another candidate with a PDUFA date in Q3 2025. The company expects this AI collaboration to enable more efficient and cost-effective scaling of their asset evaluation process.

Journey Medical (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on marketing FDA-approved dermatological prescription products, has announced its participation in the 37th Annual ROTH Conference from March 16-18, 2025, in Dana Point, California.

President and CEO Claude Maraoui will lead a fireside chat on Tuesday, March 18 at 12:30 p.m. PT and will be available for one-on-one meetings throughout the conference. Investors can access the fireside chat webcast on Journey Medical's website investor section for approximately 30 days following the event.

Sun Pharma has announced the acquisition of Checkpoint Therapeutics (CKPT) in a deal valued at up to $355 million, offering $4.10 per share in upfront cash payment plus a contingent value right of up to $0.70 per share. The acquisition centers on UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC).

The deal represents a 66% premium to Checkpoint's closing price on March 7, 2025. The transaction, expected to close in Q2 2025, requires stockholder and regulatory approvals. Checkpoint reported minimal revenue of $0.04 million and a net loss of $27.3 million for the nine months ending September 2024, with R&D expenses of $19.3 million.

Fortress Biotech, Checkpoint's controlling stockholder, will receive royalty payments based on future cosibelimab sales and has agreed to vote in favor of the transaction.

Journey Medical (NASDAQ: DERM) announced the publication of Phase 3 clinical trial results for Emrosi™ (DFD-29) in JAMA Dermatology. The trials demonstrated superior efficacy of DFD-29 (40 mg Minocycline Hydrochloride Modified-Release Capsules) compared to both Oracea® and placebo in treating rosacea.

Key findings from the MVOR-1 and MVOR-2 trials showed:

• DFD-29 achieved 65.0% and 60.1% IGA treatment success rates respectively
• Significant reduction in inflammatory lesions compared to alternatives
• Superior reduction in erythema versus placebo
• No major safety issues reported

The FDA approved Emrosi™ in November 2024 for treating inflammatory lesions of rosacea in adults, with launch expected in early spring 2025.

Journey Medical (Nasdaq: DERM) announced its participation in the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida, from March 7-11, 2025. The company will showcase Emrosi™, their newly FDA-approved treatment for inflammatory lesions of rosacea in adults, approved in November 2024.

Emrosi™, featuring 40 mg Minocycline Hydrochloride Modified-Release Capsules (10 mg immediate release and 30 mg extended release), is positioned as the lowest-dose oral minocycline available. According to the company, it demonstrates superior clinical outcomes for rosacea compared to placebo and Oracea® while maintaining a comparable safety profile.

The AAD annual meeting, with over 350 exhibitors and nearly 20,000 attendees, including 10,000+ medical personnel, will provide Journey Medical an opportunity to present their dermatology product portfolio at booth 2181.

Fortress Biotech (FBIO) has initiated dosing in a Phase 2 clinical trial evaluating Triplex, a cytomegalovirus (CMV) vaccine, in stem cell donors. The trial aims to reduce CMV events in patients undergoing hematopoietic stem cell transplantation (HSCT).

The multicenter, placebo-controlled study is funded by the National Cancer Institute and builds upon encouraging pilot study results. Triplex works by inducing CMV-specific immune responses in donors, which is then transferred to transplant recipients through adoptive immunity.

CMV reactivation affects 60-70% of CMV-seropositive HSCT recipients, with primary infection occurring in 20-30% of CMV-seronegative recipients. The trial is being conducted across three major transplant centers in the United States. A second NCI-funded trial is planned for higher-risk transplant recipients with partial HLA matches.

Journey Medical (Nasdaq: DERM) has announced a conference call and webcast scheduled for February 5, 2025, at 4:30 p.m. ET to discuss the commercial launch plan for Emrosi™, their newly FDA-approved treatment for inflammatory lesions of rosacea in adults.

The medication, which contains 40 mg Minocycline Hydrochloride in extended-release capsules, was developed in collaboration with Dr. Reddy's Laboratories and received FDA approval in November 2024. The company is currently completing manufacturing of launch quantities for the U.S. market and preparing their dermatology-focused sales force for the product rollout.

The conference call will be accessible via phone (1-866-777-2509 domestic, 1-412-317-5413 international) and webcast through Journey Medical's website. The most common adverse reaction reported in clinical trials was dyspepsia, occurring in ≥1% of subjects treated with Emrosi compared to placebo.